Skip to main content
Log in

Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report

  • Published:
Journal of Inherited Metabolic Disease

Abstract

We have studied a knockout mouse with fumarylacetoacetate hydrolase (FAH) deficiency as a model of human hereditary tyrosinaemia type I (HT1). These mice have a phenotype very similar to the human disease, which is characterized by acute hepatic failure, renal tubular disease and hepatocarcinoma. We have previously reported on the efficacy of 2-(2-nitro-4-trifluoromethylbenzyol)-1,3-cyclohexanedione (NTBC) in preventing acute liver disease in HT1 mice. Here we present a progress report on long-term follow up (>1 year) of high-dose NTBC therapy in combination with tyrosine restriction. In vivo retroviral gene therapy was also effective in abolishing the acute liver failure of HT1. Retrovirally treated mice remained completely healthy and active for 12 months after retroviral gene transfer. However, hepatocarcinoma developed in 2/3 treated animals after 1 year. Southern blot analysis showed that the tumours did not arise from retrovirally transduced hepatocytes but from non-corrected FAH-deficient cells. These results highlight the extreme danger for tumour formation in HT1 and indicate the need for improved gene therapy that leads to the elimination of endogenous FAH-deficient liver cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

REFERENCES

  • Agsteribbe E, van Faassen H, Hartog MV, et al (1990) Nucleotide sequence of cDNA encoding human fumarylacetoacetase. Nucleic Acids Res 18: 1887.

    Google Scholar 

  • Bain MD, Purkiss P, Jones M, Bingham P, Stacey TE, Chalmers RA (1990) Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinemia type I. Eur J Pediatr 149: 637–639.

    Google Scholar 

  • Bird S, Miller NJ, Collins JE, Rice-Evans CA (1995) Plasma antioxidant capacity in two cases of tyrosinaemia type 1: one case treated with NTBC. J Inher Metab Dis 18: 123–126.

    Google Scholar 

  • Demers SI, Tanguay RM (1991a) BqlII RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1965.

    Google Scholar 

  • Demers SI, Tanguay RM (1991b) MspI RFLP in the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 6971.

    Google Scholar 

  • Demers SI, Phaneuf D, Tanguay RM (1991) Taq1 RFLP for the human fumarylacetoacetate hydrolase (FAH) gene. Nucleic Acids Res 19: 1352.

    Google Scholar 

  • Esquivel CO, Mieles L, Marino IR, et al (1989) Liver transplantation for hereditary tyrosinemia in the presence of hepatocellular carcinoma. Transplant Proc 21: 2445–2446.

    Google Scholar 

  • Gabrielli O, Maiorana A, Paris D, et al (1978) Presentation of a case of chronic type 1 tyrosinemia. Diet therapy and clinical outcome. Minerva Pediatr 30: 1329–1334.

    Google Scholar 

  • Gentz J, Lindblad B, Lindstedt S, Levy L, Shasteen W, Zetterstrom R (1967). Dietary treatment in tyrosinemia (tyrosinosis). With a note on the possible recognition of the carrier state. Am J Dis Child 113: 31–37.

    Google Scholar 

  • Giardini O, Cantani A, Kennaway NG, DÏ Eufemia P (1983) Chronic tyrosinemia associated with 4-hydroxyphenylpyruvate dioxygenase deficiency with acute intermittent ataxia and without visceral and bone involvement. Pediatr Res 27: 25.

    Google Scholar 

  • Gluecksohn-Waelsch S (1979) Genetic control of morphogenetic and biochemical differentiation: lethal albino deletions in the mouse. Cell 16: 225–237.

    Google Scholar 

  • Grenier A, Lescault A (1985) Succinylacetone. In Bergmeyer HU, ed. Methods of Enzymatic Analysis. Weinheim: VCH, 79.

    Google Scholar 

  • Grompe M, Al-Dhalimy M (1993) Mutations of the fumaryl acetoacetate hydrolase gene in four patients with tyrosinemia, type I. Hum Mutat 2: 85–93.

    Google Scholar 

  • Grompe M, Al-Dhalimy M, Finegold M, et al (1993) Loss of fumarylacetoacetate hydrolase is responsible for the neonatal hepatic dysfunction phenotype of lethal albino mice. Genes Dev 7: 2298–2307.

    Google Scholar 

  • Grompe M, St-Louis M, Demers SI, Al-Dhalimy M, Leclerc B, Tanguay RM (1994) A single mutation of the fumarylacetoacetate hydrolase gene in French Canadians with hereditary tyrosinemia type I. N Engl J Med 331: 353–357.

    Google Scholar 

  • Grompe M, Lindstedt S, Al-Dhalimy M, et al (1995) Pharmacological correction of neonatal lethal hepatic dysfunction in a murine model of hereditary tyrosinaemia type I. Nature Genetics 10: 453–460.

    Google Scholar 

  • Hirakawa DA, Olson LM, Baker DH (1984) Comparative utilization of a crystalline amino acid diet and a methionine fortified casein diet by young rats and mice. Nutr Res 4: 891–895.

    Google Scholar 

  • Holme E, Lindstedt S. (1998) Tyrosinaemia type I and NTBC (2-(2-nitro-4-tri-fluoromethylbenzoyl)-1,3-cyclohexanedione). J Inter Metab Dis 21: 507–511.

    Google Scholar 

  • Jehan P, Buchman M, Odievre M (1984) Dietary management of hereditary tyrosinemia. Apropos of 7 cases. Ann Pediatr (Paris) 31: 33–40.

    Google Scholar 

  • Jimenez-Acosta F (1994) Painful plantar callouses and mental retardation. Tyrosinemia type II. Arch Dermatol 130: 507–511.

    Google Scholar 

  • Kelsey G, Schütz G (1993) Lessons from lethal albino mice. Curr Opin Gen Dev 3: 259–264.

    Google Scholar 

  • Klebig ML, Russell LB, Rinchik EM (1992) Murine fumarylacetoacetate hydrolase (Fah) gene is disrupted by a neonatally lethal albino deletion that defines the hepatocyte-specific developmental regulation 1 (hsdr-1) locus. Proc Natl Acad Sci USA 89: 1363–1367.

    Google Scholar 

  • Kvittingen EA, Jellum E, Stokke O, et al (1986) Liver transplantation in a 23-year-old tyro-sinaemia patient: effects on the renal tubular dysfunction. J Inher Metab Dis 9: 216–224.

    Google Scholar 

  • Kvittingen EA, Rootwelt H, Brandtzaeg P, Bergan A, Berger R (1993) Hereditary tyrosinemia type I. Self-induced correction of the fumarylacetoacetase defect. J Clin Invest 91: 1816–1821.

    Google Scholar 

  • Kvittingen EA, Rootwelt H, Berger R, Brandtzaeg P (1994) Self-induced correction of the genetic defect in tyrosinemia type I. J Clin Invest 94: 1657–1661.

    Google Scholar 

  • Labelle Y, Phaneuf D, Leclerc B, Tanguay RM (1993a) Characterization of the human fumarylacetoacetate hydrolase gene and identification of a missense mutation abolishing enzymatic activity. Hum Mol Genet 2: 941–946.

    Google Scholar 

  • Labelle Y, Puymirat J, Tanguay RM (1993b) Localization of cells in the rat brain expressing fumarylacetoacetate hydrolase, the deficient enzyme in hereditary tyrosinemia type 1. Biochim Biophys Acta 1180: 250–256.

    Google Scholar 

  • Lindblad B, Lindstedt S, Steen G (1977) On the enzymic defects in hereditary tyrosinemia. Proc Natl Acad Sci USA 74: 4641–4645.

    Google Scholar 

  • Lindstedt S, Holme E, Lock EA, Hjalmarson O, Strandvik B (1992) Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 340: 813–817.

    Google Scholar 

  • Markowitz D, Goff S, Bank A (1988a) Construction and use of a safe and efficient amphotropic packaging cell line. Virology 167: 400–406.

    Google Scholar 

  • Markowitz D, Goff S, Bank A (1988b) A safe packaging line for gene transfer: separating viral genes on two different plasmids. J Virol 62: 1120–1124.

    Google Scholar 

  • McLachlin JR, Mittereder N, Daucher MB, Kadan M, Eglitis MA (1993) Factors affecting retroviral vector function and structural integrity. Virology 195: 1–5.

    Google Scholar 

  • Michals K, Matolon R, Wong PW (1978) Dietary treatment of tyrosinemia type I: importance of methionine restriction. J Am Diet Assoc 73: 507–514.

    Google Scholar 

  • Mieles LA, Esquivel CO, Van Thiel DH, et al (1990) Liver transplantation for tyrosinemia. A review of 10 cases from the University of Pittsburgh. Dig Dis Sci 35: 153–157.

    Google Scholar 

  • Miller SA, Dykes DD, Polesky HF (1988) A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 16: 1215.

    Google Scholar 

  • Mitchell GA, Lambert M, Tanguay RM (1995) Hypertyrosinemia. In Scriver CR, Beaudet AL, Sly W, Valle D, eds. T he Metabolic and Molecular Bases of Inherited Disease, 7th edn. New York: MacGraw-Hill, 1077–1106.

    Google Scholar 

  • Overturf K, Al-Dhalimy M, Tanguay R, et al (1996) Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I. Nature Genetics 12: 266–273.

    Google Scholar 

  • Overturf K, Al-Dhalimy M, Ou CN, et al (1997) Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene T her 8: 513–521.

    Google Scholar 

  • Pérez-Cerdà C, Merinero B, Sanz P, et al (1995) Liver transplantation in nine Spanish patients with tyrosinaemia type I. J Inher Metab Dis 18: 119–122.

    Google Scholar 

  • Paradis K, Weber A, Seidman EG, et al (1990) Liver transplantation for hereditary tyrosinemia: the Quebec experience. Am J Hum Genet 47: 338–342.

    Google Scholar 

  • Phaneuf D, Labelle Y, Bérubé D, et al (1991) Cloning and expression of the cDNA encoding human fumarylacetoacetate hydrolase, the enzyme deficient in hereditary tyrosinemia: assignment of the gene to chromosome 15. Am J Hum Genet 48: 525–535.

    Google Scholar 

  • Phaneuf D, Lambert M, Laframboise R, Mitchell G, Lettre F, Tanguay RM (1992) Type 1 hereditary tyrosinemia. Evidence for molecular heterogeneity and identification of a causal mutation in a French Canadian patient. J Clin Invest 90: 1185–1192.

    Google Scholar 

  • Pronicka E, Rowinska E, Bentkowski Z, Zawadzki J, Holme E, Lindstedt S (1996) Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC). J Inher Metab Dis 19: 234–238.

    Google Scholar 

  • Riudor E, Ribes A, Lloret J, et al (1991) Liver transplantation in two children with tyrosinaemia type I: biochemical aspects. J Inher Metab Dis 14: 281–284.

    Google Scholar 

  • Rootwelt H, Kvittingen EA, Hoie K, et al (1992) The human fumarylacetoacetase gene: characterisation of restriction fragment length polymorphisms and identification of haplotypes in tyrosinemia type 1 and pseudodeficiency. Hum Genet 89: 229–233.

    Google Scholar 

  • Rootwelt H, Chou J, Gahl WA, et al (1994) Two missense mutations causing tyrosinemia type 1 with presence and absence of immunoreactive fumarylacetoacetase. Hum Genet 93: 615–619.

    Google Scholar 

  • Ruppert S, Kelsey G, Schedl A, Schmid E, Thies E, Schütz G (1992) Deficiency of an enzyme of tyrosine metabolism underlies altered gene expression in newborn liver of lethal albino mice. Genes Dev 6: 1430–1443.

    Google Scholar 

  • Salt A, Barnes ND, Rolles K, Calne RY, Clayton PT, Leonard JV (1992) Liver transplantation in tyrosinaemia type 1: the dilemma of timing the operation. Acta Paediatr 81: 449–452.

    Google Scholar 

  • Sambrook J, Fritsch EF, Maniatis T (eds) (1989) Molecular Cloning: A Laboratory Manual. 2nd edn. Cold Spring Harbor: Cold Spring Harbor Laboratory Press.

    Google Scholar 

  • Sokal EM, Bustos R, Van HF, Otte JB (1992) Liver transplantation for hereditary tyrosinemiäearly transplantation following the patient's stabilization. Transplantation 54: 937–939.

    Google Scholar 

  • St-Louis M, Leclerc B, Laine J, Salo MK, Holmberg C, Tanguay RM (1994) Identification of a stop mutation in five Finnish patients su.ering from hereditary tyrosinemia type I. Hum Mol Genet 3: 69–72.

    Google Scholar 

  • Suzuki Y, Konda M, Imai I, Imamura H, Shimao S, Okaka T (1987) Effect of dietary treatment on the renal tubular function in a patient with hereditary tyrosinemia. Int J Pediatr Nephrol 8: 171–176.

    Google Scholar 

  • Tada K, Wada Y, Yazaki N, Yokoyama T, Nakagawa H (1968) Dietary treatment of infantile tyrosinemia. T ohoku J Exp Med 95: 337–344.

    Google Scholar 

  • Tanguay RM, Valet JP, Lescaul t A, et al (1990) Different molecular basis for fumarylacetoacetate hydrolase deficiency in the two clinical forms of hereditary tyrosinemia (type I). Am J Hum Genet 47: 308–316.

    Google Scholar 

  • Timmers C, Grompe M (1996) Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I. Hum Mutat 7: 367–369.

    Google Scholar 

  • van-Spronsen FJ, Smit GP, Wijburg FA, Thomasse Y, Visser G, Heymans HS (1995) Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation. J Inher Metab Dis 18: 111–114.

    Google Scholar 

  • Vrancken Peeters MJ, Lieber A, Perkins J, Kay MA (1996) Method for multiple portal vein infusions in mice: quantitation of adenovirus-mediated hepatic gene transfer. Biotechniques 20: 278–285.

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Grompe, M., Overturf, K., Al-Dhalimy, M. et al. Therapeutic trials in the murine model of hereditary tyrosinaemia type I: A progress report. J Inherit Metab Dis 21, 518–531 (1998). https://doi.org/10.1023/A:1005462804271

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1005462804271

Keywords

Navigation